Castle Biosciences CSTL Business Segments — Clinical studies and publication costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept cstl:ClinicalStudiesAndPublicationCosts.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's business segments — clinical studies and publication costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's business segments — clinical studies and publication costs?
- Castle Biosciences (CSTL) reported business segments — clinical studies and publication costs of $2.54M in Q1 2026.
- How has Castle Biosciences's business segments — clinical studies and publication costs changed year-over-year?
- Castle Biosciences's business segments — clinical studies and publication costs increased by 21.9% year-over-year, from $2.09M to $2.54M.
- What is the long-term trend for Castle Biosciences's business segments — clinical studies and publication costs?
- Over 3 years (2022 to 2025), Castle Biosciences's business segments — clinical studies and publication costs has grown at a -0.8% compound annual growth rate (CAGR), from $9M to $8.78M.
- What does business segments — clinical studies and publication costs mean?
- Represents investments in clinical research, validation studies, and scientific publications necessary to support product efficacy claims. These costs are essential for maintaining competitive advantage and securing physician adoption in the healthcare market.